Zinc for Common Cold

Verdict: Promising but unproven; depends on form and dose

High-dose zinc acetate or gluconate lozenges started within the first day of a cold may shorten its duration, but the evidence is inconsistent and low-certainty, so zinc is not a proven cold remedy and does not prevent colds at all.

U ⚫ U Unverified Insufficient Evidence

🔬Why this grade7-layer evidence engine

The grade is Unverified (Insufficient Evidence) because the trials point in different directions and hinge on the exact product used. Meta-analyses of high-dose lozenges (>75 mg/day elemental zinc) by Hemila report roughly a 33-40% shorter cold (PMID 28515951; PMID 39435383), yet the 2024 Cochrane review (PMID 38719213, 34 trials, n=8,526) found only about a 2-day reduction at low certainty and no clear effect on symptom severity. A 2020 randomized trial of zinc acetate lozenges (PMID 31980506) failed outright, with the zinc group actually recovering more slowly afterward.

Crucially, the signal is treatment-only and form-specific. The same Cochrane analysis showed zinc does not prevent colds (relative risk 0.93, 95% CI 0.85-1.01), and benefit appears confined to acetate or gluconate lozenges at high doses begun within 24 hours; lower doses and ordinary oral capsules show no effect. Lozenges also commonly cause taste disturbance and stomach upset.

Authorities reflect this caution rather than endorsement. EFSA recognizes only zinc's role in 'normal function of the immune system,' the NHS says diet supplies enough zinc, and WHO backs zinc solely for childhood diarrhea, not colds. Clinics agree it 'may' help: Mayo and Cleveland Clinic cite about a one-day reduction, Harvard a roughly two-day reduction but calls the response 'lukewarm.' No regulator approves a 'zinc treats colds' claim.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable

Raw score 0.42

← counter-evidence / ineffectiveeffective / strong evidence →

Final grade

U · Insufficient Evidence

Confidence

79%

Broadly consistent

Evidence level

Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive

L11 AI re-checkIndependent read

0.20

L5 Clinical bodiesAuthoritative stance

0.40

L2 PubMedPrimary literature

0.45

L3 MechanismPlausibility

0.45

L1 ExamineGlobal benchmark

0.50

Against Mixed Supports

▸View the full decision path (audit trail)

compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.418
tier_from_score — 依分數區間映射至 tier letter
apply_hec_rules — 高階證據未達主導 (1 positive vs 1 negative)，由 raw_score 決定
tier_strict_requirement_check — | C→U 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

PMID: 38719213 統合分析 n = 8,526

Finding: Zinc taken for treatment of a cold may reduce mean cold duration by approximately 2 days vs placebo, but evidence certainty is low. No strong evidence of effect on symptom severity. Zinc supplementation showed little to no reduction in risk of developing a cold (RR 0.93, 95% CI 0.85-1.01). Increased risk of non-serious adverse events (taste disturbance, GI upset).

Mixed funding

View on PubMed

PMID: 31980506 隨機對照試驗 n = 253

Finding: Commercially available zinc acetate lozenge (78 mg elemental zinc/day) was NOT effective in shortening the common cold. No difference in 10-day recovery rate (rate ratio 0.68, 95% CI 0.42-1.08; p=0.10). Zinc participants recovered slower than placebo during 2 days post-intervention (p=0.003).

Mixed funding

View on PubMed

PMID: 28515951 統合分析 n = 575

Finding: Across 7 RCTs (>75 mg/day elemental zinc lozenges), mean cold duration shortened by 33% vs placebo (95% CI 21%-45%, p=1e-7). Zinc acetate trials shortened colds by 40%; zinc gluconate by 28%; difference between salts not statistically significant (12 percentage points, 95% CI -12 to +36). Low-dose lozenges (<75 mg/day) showed no effect.

Mixed funding

View on PubMed

PMID: 39435383 統合分析

Finding: Re-analysis of high-dose zinc acetate/gluconate lozenge trials in adults: 37% reduction in cold duration (95% CI 27%-46%). Three acetate trials gave recovery rate ratio 3.1 (95% CI 2.1-4.7) favoring zinc. Argues Cochrane 2024 pooled heterogeneous formulations and obscured lozenge-specific effect.

Mixed funding

View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4b EU EFSA

Supportive

contributes to normal function of the immune system source↗

L4c UK NHS

Cautious

You should be able to get all the zinc you need from your daily diet source↗

L4d TW TFDA / 衛福部

Supportive

鋅之每日最高攝食量不得超過30 mg source↗

L4e WHO

Supportive

zinc has been recommended by WHO and UNICEF as the only treatment to be coupled with oral rehydration salts for the treatment of all diarrhoea episodes source↗

L5a NIH Office of Dietary Supplements

Supportive

Zinc is an essential mineral involved in numerous aspects of cellular metabolism source↗

L5b Mayo Clinic

Cautious

zinc may shorten the length of a cold source↗

L5c Cleveland Clinic

Cautious

Zinc may shorten the length of a cold by about a day. source↗

L5d Harvard Health

Cautious

shortened the duration of symptoms by an average of two days source↗

✓PMID 100% verifiedevery citation checked via NCBI Entrez

🔬4 PubMed studiesindependently re-checked by multiple sub-agents

engine_version: v1.0 claim_id: CLM-COND-common-cold-INT-zinc-001 繁體中文版 →